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453Coronary Obstruction Following
Transcatheter Aortic Valve Implantation
A Systematic Review
Objectives This study sought to evaluate, through a systematic review of the published data, the
main baseline characteristics, management, and clinical outcomes of patients suffering coronary ob-
struction as a complication of transcatheter aortic valve implantation (TAVI).
Background Very few data exist on coronary obstruction after TAVI.
Methods Studies published between 2002 and 2012, with regard to coronary obstruction as a com-
plication of TAVI, were identiﬁed with a systematic electronic search. Only the studies reporting data
on the main baseline and procedural characteristics, management of the complication, and clinical
outcomes were analyzed.
Results A total of 18 publications describing 24 patients were identiﬁed. Most (83%) patients were
omen, with a mean age of 83  7 years and a mean logistic European System for Cardiac Opera-
tive Risk Evaluation score of 25.1  12.0%. Mean left coronary artery (LCA) ostium height and aortic
root width were 10.3  1.6 mm and 27.8  2.8 mm, respectively. Most patients (88%) had received
a balloon-expandable valve, and coronary obstruction occurred more frequently in the LCA (88%).
Percutaneous coronary intervention was attempted in 23 cases (95.8%) and was successful in all but
2 patients (91.3%). At 30-day follow-up, there were no cases of stent thrombosis or repeat revascu-
larization, and the mortality rate was 8.3%.
Conclusions Reported cases of coronary obstruction after TAVI occurred more frequently in women, in
patients receiving a balloon-expandable valve, and the LCA was the most commonly involved artery.
Percutaneous coronary intervention was a feasible and successful treatment in most cases. Continuous
efforts should be made to identify the factors associated with this life-threatening complication to imple-
ment the appropriate measures for its prevention. (J Am Coll Cardiol Intv 2013;6:452–61) © 2013 by
the American College of Cardiology FoundationTranscatheter aortic valve implantation (TAVI) has
emerged as an alternative to surgical aortic valve replace-
ment in those patients considered at very high or prohibitive
risk for surgery (1). Despite its more widespread adoption as
a treatment option and the increasing experience of the
centers, TAVI is still associated with complications, such as
vascular/bleeding and cerebrovascular events, conduction
abnormalities requiring permanent pacemaker implantation,
and significant residual aortic regurgitation (1). The rela-
tively high rate of such complications has made possible an
accurate evaluation of their predictive factors and clinical
consequences, and this does indeed represent a first step in
the way of implementing appropriate preventive measures
and treatment. Nonetheless, TAVI has also been associated
with very rare but life-threatening complications, such as
coronary ostia obstruction. Specific clinical data on this
important complication—apart from some reports on its
incidence (usually 1%) in some TAVI series (2–8)—have
been scarce and restricted to case reports and small caseseries, precluding any appropriate evaluation of the baseline
characteristics of patients suffering this complication as well
as its management and clinical impact. The objective of the
present study was to provide further insight into the baseline
characteristics, management, and clinical outcomes of pa-
tients with coronary obstruction as a complication of TAVI
through a systematic review of all the studies on TAVI and
coronary obstruction published thus far.
Methods
All relevant papers published in English about TAVI and
coronary obstruction published between December 2002 and
July 2012 were systematically searched in BioMedCentral,
Google Scholar, and PubMed. The following query terms
were used: aortic stenosis, transcatheter aortic valve implanta-
tion, transcatheter aortic valve replacement, transcatheter heart
valve, heart valve prosthesis implantation, coronary stenosis,
coronary occlusion, and coronary obstruction. Further studies
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454were sought by means of a manual
search of secondary sources, in-
cluding references from primary
papers (backward snowballing)
and contacts with international
experts.
Citations were first screened
at the title/abstract level by 2
independent reviewers (HBR,
LNF) and retrieved as complete
manuscripts if potentially perti-
nent. Divergences were resolved
after consensus, to gather all the
pertinent case reports and case series concerning coronary
obstruction in TAVI. Published papers that included only
the incidence of the complication without any case descrip-
tion were excluded from this analysis.
Gathered data included baseline clinical, echocardio-
graphic, and computed tomography (CT) characteristics.
The CT variables included data on left coronary artery
(LCA) ostium height from aortic annulus, severity and
distribution of valve calcification, and aortic root and annu-
lus diameters. Procedural data on the type and size of the
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CT  computed tomography
LCA  left coronary artery
PCI  percutaneous
coronary intervention
TAVI  transcatheter aortic
valve implantation
Table 1. Individual Data on Baseline Clinical and Procedural Characteristic
Patient#
(Ref#) Age Sex
Previous
CABG
Logistic
EuroSCORE (%)
Mean Aortic
Gradient (mm Hg)
1 (9) 85 F No 13.3 88
2 (10) 87 — No — —
3 (11) 85 F No 18.0 45
4 (12) 81 F No 21.0 —
5 (12) 85 F No 23.8 —
6 (12) 80 M No 31.0 —
7 (13) 86 F No 24.3 51
8 (13) 78 F Yes 51.5 46
9 (13) 80 F No 25.3 58
10 (13) 88 F No 22.0 55
11 (13) 82 M No 20.7 43
12 (14) 86 M No — —
13 (15) 87 F No — 60
14 (16) 87 F No — 70
15 (17) 58 F No — 57
16 (18) 86 F No — —
17 (19) 82 F No — —
18 (20) 68 F No 8.8 46
19 (21) 86 F No 31.2 55
20 (22) 76 F No 9.1 90
21 (23) 86 F No — 68
22 (24) 86 F No 45.0 —
23 (25) 89 F No 25.3 65
24 (26) 87 M No — —
SAPEIN and CoreValve (Medtronic, Minneapolis, Minnesota).
CABG  coronary artery bypass graft; CAD  previous coronary artery disease; EuroSCORE  Etransfemoral.transcatheter valve, approach, and clinical presentation and
management of coronary obstruction were recorded. Finally,
data on in-hospital or 30-day mortality and clinical status at
follow-up, including the need for repeat revascularization,
were also gathered.
Categorical variables were reported as n (%), and contin-
uous variables were reported as mean  SD. Group com-
parisons were performed with the chi-square test for cate-
gorical variables and Student t test adjusted for multiple
comparisons (Bonferroni method) for continuous variables.
The results were considered significant with p values 0.05.
All analyses were conducted with the statistical package SAS
(version 9.3, SAS Institute, Inc., Cary, North Carolina).
Results
Between January 2002 and May 2012, 19 publications describ-
ing a total of 27 patients who had experienced coronary
obstruction related to a TAVI procedure were identified
(9–27). All studies referred to single case reports or small
series, with a maximum of 5 reported cases of coronary
obstruction. Three cases with previous surgical aortic valve
prosthesis (“valve-in-valve” procedure) were excluded from this
Aortic
ulus (mm)
Aortic
Root (mm)
LCA Height
(mm) Approach
Valve
Type
Valve
(mm)
22.0 — 9.1 TA SAPIEN 26
— — — TF SAPIEN —
— — — TF SAPIEN 23
— — 12 TA SAPIEN 26
— — 12 TF SAPIEN XT 23
— — 12 TA SAPIEN XT 29
22.4 31.3 9.7 TF SAPIEN 26
19.3 27.8 10.3 TA SAPIEN 23
20.9 26.4 9.0 TA SAPIEN 23
18.0 26.2 11.0 TA SAPIEN 23
22.1 33.0 9.0 TA SAPIEN 23
— — — TF SAPIEN 23
20.0 — — TF SAPIEN 23
20.0 — — TA SAPIEN 23
— — — TF SAPIEN 26
— — — TF SAPIEN 23
— — 7.0 TF SAPIEN 23
21.6 26.4 — TA SAPIEN 26
— — 10.2 TF SAPIEN 23
24.0 — — TF SAPIEN XT 26
— — — TF SAPIEN XT 23
20.0 27.0 11.0 TF CoreValve 26
20.0 — 12.0 TF CoreValve 26
— — — TF CoreValve 29
System for Cardiac Operative Risk Evaluation; LCA  left coronary artery; TA  transapical; TF s
Ann
uropean
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455analysis (24,27), leading to a final study population of 24
patients. The main baseline clinical characteristics were avail-
able in all patients. The CT data on left main ostium height
and annulus and aortic root measurements were reported in 13,
12, and 8 patients, respectively. No data were reported on the
severity and distribution of valve calcification. Procedural and
clinical data on the clinical presentation, diagnosis, and man-
agement of the coronary obstruction were available in all
patients. All studies reported data on in-hospital outcomes, 12
studies (including 16 patients) reported data on 30-day out-
comes, and 11 studies (including 14 patients) reported data at
follow-up.
The main clinical, echocardiographic, CT, and proce-
dural characteristics of the patients are shown in Tables 1
(individual data) and 2 (mean data). Mean age of the study
population was 83  7 years, and most patients were
women (83.3%). The main baseline characteristics of the
study population compared with those reported in the
largest TAVI registries (3,4,6–8,28–31) (pooled data) and
the PARTNER (Placement of Aortic Transcatheter Valve)
trial (5,32) are shown in Figure 1. The CT data revealed a
Table 2. Baseline Clinical, Echocardiographic, CT, and Procedural
Characteristics of the Study Population (N  24)
Clinical variables
Age, yrs 82.5 7.0
Female 20 (83.3%)
NYHA
I–II 18.2%
III–IV 81.8%
Previous CABG 1 (4.2%)
Logistic EuroSCORE (%) 25.1 12.0
Echocardiographic and CT data
Mean aortic gradient, mm Hg 59.8 14.5
Indexed aortic valve area, cm2/m2 0.43 0.09
Aortic annulus, mm 20.8 1.6
Left main height, mm 10.3 1.6
Aortic root width, mm 27.8 2.8
Procedural data
Approach
TF 15 (62.5%)
TA 9 (37.5%)
Valve type
SAPIEN and SAPIEN XT 21 (87.5%)
23 mm 13 (54.2%)
26 mm 6 (25.0%)
29 mm 1 (4.2%)
Unknown 1 (4.2%)
CoreValve 3 (12.5%)
26 mm 2 (8.3%)
29 mm 1 (4.2%)
Ratio valve/annulus 1.19 0.07
Values are mean SD or n (%).
NYHA  New York Heart Association functional classification; PCI  percutaneous coronaryintervention; other abbreviations as in Table 1.mean LCA ostia height of 10.3  1.6 mm and aortic root
width of 27.8  2.8 mm. The mean values of LCA height
and aortic root diameter compared with the values obtained
in a previous population of patients with and without aortic
stenosis (33,34) as well as that of patients referred for TAVI
(35) are shown in Figure 2. A balloon-expandable Edwards
valve (Edwards Lifesciences, Irvine, California) was used in
most (87.5%) cases.
The main data on clinical presentation and management
of coronary obstruction are shown in Tables 3 (individual
data) and 4 (mean data). Most (87.5%) cases presented with
persistent severe hypotension. Onset of symptoms occurred
immediately after valve implantation in 20 patients (83.3%),
within the first few hours after the procedure in 2 patients
(8.3%), and within the first 2 days after the procedure in
another 2 patients (8.3%). Coronary obstruction occurred
more frequently in the LCA (83.3%), and the diagnosis was made
by coronary angiography in all patients but 1 (post-mortem).
Coronary obstruction was related to the displacement of a
calcified native aortic valve leaflet toward the coronary ostium
in all patients, except for 1 patient with aortic valve cusp
shearing and migration into the LCA.
Percutaneous coronary intervention (PCI) was attempted
in 23 patients (95.8%) and was successful in all but 2
(91.3%). At least 1 stent was implanted at the coronary ostia
in 20 patients. Significant compression of the stent requir-
ing the implantation of a second stent occurred in 3
patients, whereas conversion to open heart surgery was
required in 2 patients. The 2 unsuccessful PCI cases
consisted of a failure to cross the obstruction with the
coronary wire, requiring emergency coronary artery bypass
graft (CABG), and a failure to re-establish coronary flow
despite successful stent implantation, leading to continuous
cardiogenic shock and death.
Hospital mortality rate was 8.3%, and all patients who
had successful PCI survived and were discharged from the
hospital at a mean of 7  4 days after the intervention, with
no cases of stent thrombosis or repeat revascularization.
Data at follow-up (mean of 10  6 months) were available
in 14 patients, and all of them were alive and in New York
Heart Association functional class I or II at that time. One
patient needed repeat revascularization due to stent reste-
nosis at 4-month follow-up.
Discussion
The main findings of this systematic review of the published
data on symptomatic coronary obstruction after TAVI
showed that this complication occurred more frequently in
women and in patients with no prior CABG. In these cases,
the mean height of the LCA ostium was approximately 10
mm (range 7 to 12 mm), and the mean diameter of the
aortic root was approximately 28 mm (range 26 to 33 mm).
Also, the vast majority of reported cases of coronary ob-
r
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456struction post-TAVI occurred in patients who had received
a balloon-expandable valve. Clinical presentation included:
persistent severe hypotension, ST-segment changes, and
ventricular arrhythmias, all of which occurred immediately
after valve implantation in most cases. An LCA ostia
obstruction was more frequent than RCA obstruction, and
most patients were treated with PCI, which was successful
in approximately 90% of them. However, conversion to
open heart surgery and mechanical hemodynamic support
were required in approximately 8% and 25% of PCI at-
tempts, respectively. Importantly, significant compression of
the implanted stent was observed in 13% of the cases,
requiring the implantation of a second stent in all of them.
There were no cases of acute stent thrombosis or repeat
revascularization, and the in-hospital mortality rate for the
entire study population was 8.3% (0% in those patients with
Figure 1. Main Baseline Clinical Characteristics
Main baseline characteristics of the study population compared with the large
and the PARTNER (Placement of Aortic Transcatheter Valve) trials (5,32), includ
Risk Evaluation (EuroSCORE) (C), and prior coronary artery bypass graft (CABG)a successful PCI).Coronary obstruction after TAVI was first described in
the first TAVI experimental porcine model (36), and this
potential complication was subsequently confirmed by other
authors in different experimental models (37). The occur-
rence of coronary obstruction after TAVI in humans was
first described in 2006 (10), and its reported incidence has
usually been 1%, ranging from 0% to 4.1% in contempo-
ary series (10,13,38–40). The rates of coronary obstruction
n recent TAVI registries and in the PARTNER trial are
ummarized in Table 5.
Factors associated with coronary obstruction after TAVI. The
most frequent mechanism associated with coronary obstruc-
tion after TAVI has been the displacement of the calcified
native cusp over the coronary ostium, and this has also been
confirmed by the present review of the published data. In
scatheter aortic valve implantation registries (3,4,6–8,28–31) (pooled data)
ean age (A), female sex (B), logistic European System for Cardiac Operative
Coronary obstruction versus other groups.st tran
ing mfact, no cases of coronary obstruction related to the struts of
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457the transcatheter valve frame or to the cuff/leaflets of the
transcatheter valve itself have been reported to date. Al-
though the final mechanism leading to coronary obstruction
after TAVI is well understood, the risk factors that predis-
pose a patient to its occurrence remain largely unknown. A
low position of the coronary ostia with respect to the aortic
annulus has been highlighted as one of the most important
factors contributing to this complication, and it has been
suggested that a coronary ostia height cutoff 10 mm
increases the risk of coronary obstruction during TAVI
(41,42). In a recent post-mortem study, including 51
normal hearts, the mean LCA height, as determined by the
LCA distance to the bottom of the corresponding sinus, was
Figure 2. Computed Tomography Data
Mean values of the left coronary artery (LCA) height (A) and aortic root
diameter (B) of patients with coronary obstruction after transcatheter aortic
valve implantation compared with the values obtained from previous com-
puted tomography studies, including patients with and without aortic ste-
nosis (33–35). *Coronary obstruction versus other groups.12.6  2.6 mm (43). In another study that evaluated the (ortic root with multislice CT in 169 patients with and
ithout aortic stenosis, the mean distance from the basal
ttachment point of the aortic valve leaflets to the ostium of
he LCA was 14.4  2.9 mm, with no differences between
atients with and without aortic stenosis (34). Akhtar et al.
33) found that aortic stenosis was associated with a shorter
istance from the aortic valve annulus to the LCA ostium
13.4 3.2 mm vs. 15.6 2.7 mm; p 0.01). The present
study showed that the mean height of the LCA ostium in
the reported cases of coronary obstruction after TAVI was
10.3 mm (range 7 to 12 mm), a mean value that seems to
be significantly lower (2 to 5 mm) compared with that
reported in prior pathological and CT studies in patients
with and without aortic stenosis (Fig. 2). However, this
mean coronary ostium height value was higher than the
previously suggested 10-mm “safety” cutoff, and indeed,
approximately 60% of the cases with coronary obstruction
after TAVI had a coronary ostia height 10 mm. This
suggests that factors other than a short-distance between the
aortic annulus and coronary ostia might also be involved in
the occurrence of this complication.
The severity of valve calcification and, especially, the
presence of bulky calcium nodules on the left or right aortic
leaflets have also been suggested as important predictive
factors for coronary obstruction after TAVI. However, the
degree of valve calcification or the presence of calcium
nodules was not described in any of the reports included in
the present review, suggesting that this factor was either not
evaluated or not considered. Also, a narrow aortic root with
shallow sinuses of Valsalva leaving little room to accommo-
date the calcified native aortic leaflets after valve deployment
might also be an important factor associated with coronary
obstruction after TAVI. In this series, the mean aortic root
diameter was approximately 28 mm, which was lower than
the 30-mm diameter reported in previous studies evalu-
ating aortic root geometry (33,35) (Fig. 2). However, most
reports included in the present review evaluated the aortic
root diameter by echocardiography, and it has been shown
that echocardiography tends to underestimate aortic root
diameters compared with multislice CT (34,44). Thus, we
cannot draw firm conclusions about the role of aortic
morphology, and in particular the degree of aortic root
effacement, in relation to this complication.
Analysis of the clinical characteristics of the patients who
suffered coronary obstruction after TAVI revealed a mean
age (82.5  7 years) and risk profile (mean logistic Euro-
pean System for Cardiac Operative Risk Evaluation score:
25.1 12) similar to those reported in most previous TAVI
tudies (Fig. 1). However, up to 83% of the patients
uffering this complication were women, and this is a
ignificantly higher rate in comparison with the approxi-
ately 50% prevalence of women in most TAVI studiesFig. 1). Moreover, it has been shown that women have a
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458smaller aortic root (45); this, together with lower coronary
ostia height, might partially explain the increased incidence
of this complication among women. Also, the rate of prior
CABG (4.2%) was much lower than in prior TAVI studies,
confirming the “protective effect” of CABG against symp-
tomatic coronary ostia obstruction.
With regard to procedural characteristics, most reported
patients who suffered coronary obstruction after TAVI had
received a balloon-expandable Edwards valve. Data from
previous TAVI registries also showed a slightly higher rate
of coronary obstruction after balloon-expandable (0.4%)
versus self-expandable (0.2%) valve implantation (Table 5)
2–4,6–8). Although the frame characteristics of the trans-
atheter valves (straight stainless steel or cobalt chromium
s. nitinol) and the mechanisms for valve implantation
balloon-expandable vs. self-expandable) might partially
xplain these differences, the criteria with regard to
inimal sinus of Valsalva diameter and coronary ostia
eight requirements differ between the 2 transcatheter
alves (SAPIEN and CoreValve, Medtronic, Minneapo-
is, Minnesota), and this might also explain the higher
Table 3. Individual Data on Clinical Presentation and Management of Coro
Patient#
(Ref#)
Coronary
Obstruction
Clinical Presentation T
Severe
Hypotension
ST-Segment
Changes
Ventricular
Arrhythmias or CPR P
1 (9) Both Yes Yes No Y
2 (10) LCA Yes No No N
3 (11) LCA Yes Yes Yes Y
4 (12) LCA Yes Yes Yes Y
5 (12) RCA Yes Yes No Y
6 (12) RCA Yes Yes Yes Y
7 (13) LCA Yes Yes No Y
8 (13) LCA Yes No Yes Y
9 (13) LCA Yes No Yes Y
10 (13) LCA Yes Yes No Y
11 (13) LCA No No No Y
12 (14) LCA Yes No No Y
13 (15) LCA Yes No Yes Y
14 (16) LCA Yes No Yes Y
15 (17) RCA Yes Yes No Y
16 (18) LCA Yes Yes No Y
17 (19) LCA Yes Yes Yes Y
18 (20) LCA Yes Yes No Ye
19 (21) LCA Yes No Yes Ye
20 (22) LCA Yes No Yes Ye
21 (23) LCA Yes Yes No Ye
22 (24) LCA No Yes No Ye
23 (25) LCA No No No Ye
24 (26) LCA Yes No Yes Ye
BMS bare-metal stent(s); CABG coronary artery bypass graft; CPR cardiopulmonary resuscitation; D
coronary artery.ate of coronary obstruction observed with the Edwards pvalve system. Whereas no specific formal recommendation
for sinus of Valsalva width and coronary ostia height is
provided for the implantation of the Edwards valve, a
recommendation of a sinus of Valsalva width 27 mm
(for the 26-mm CoreValve) or 28 mm (for the 29-mm
CoreValve) mm and a coronary height14 mm is provided
by the manufacturer for the implantation of the CoreValve
system. These specific recommendations, although probably
not followed strictly by all CoreValve implanting centers,
might have prevented a significant number of coronary
obstructions with the CoreValve system.
Clinical presentation and management of coronary obstruc-
tion after TAVI. The vast majority of patients presented with
ersistent severe hypotension after valve implantation, and
pproximately 50% and 25% of them also had ST-segment
hanges (approximately one-half of them with ST-segment
levation) and procedural ventricular arrhythmias, respec-
ively. This clinical presentation could be explained by the
act that approximately 90% of the patients had LCA
nvolvement, thus resulting in significant left ventricular
schemia. Therefore, it is of major clinical importance in the
bstruction
ent
Successful
PCI
Stent
Type
Need for
Hemodynamic Support
Hospital
Stay (days)
In-Hospital
DeathABG
No Yes BMS No 11 No
No — — No 5 Yes
No Yes DES No 5 No
No Yes BMS Yes 13 No
Yes No — Yes 12 No
No Yes — No 14 No
No Yes DES No 4 No
No No BMS Yes 0 Yes
No Yes BMS No 5 No
No Yes BMS No 4 No
No Yes — No 3 No
No Yes BMS No — No
No Yes BMS Yes 5 No
No Yes BMS No 5 No
No Yes BMS No 4 No
No Yes DES No — No
No Yes DES Yes 8 No
No Yes BMS No 5 No
No Yes BMS No — No
No Yes DES No 11 No
No Yes Both No — No
No Yes BMS No — No
No Yes BMS No — No
No Yes DES Yes — No
ug-eluting stent(s); LCA left coronary artery; PCI percutaneous coronary intervention; RCA rightnary O
reatm
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ES drresence of persistent severe hypotension after valve implan-
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 5 , 2 0 1 3 Ribeiro et al.
MA Y 2 0 1 3 : 4 5 2 – 6 1 Coronary Obstruction in TAVI
459tation, even in the absence of ECG changes, that prompt
echocardiography be performed to look for new segmental
abnormalities and/or coronary angiography to look for
coronary obstruction. Interestingly, both in normal post-
mortem hearts and in a recent study examining the aortic
root with multislice CT, the distance from the LCA ostium
to the basal attachment point of the aortic valve leaflet was
lower as compared with the right coronary ostium, which
might explain why coronary obstruction after TAVI is more
frequent on the left side (34,43).
The present study showed that PCI was the preferred
strategy for the treatment of coronary obstruction after
TAVI. It is noteworthy that PCI was feasible and associated
with a 91.3% success rate. Bare-metal stents were used more
frequently than drug-eluting stents, and there were no cases
of stent thrombosis or need for repeat revascularization
during the hospital stay. However, 3 patients (13%) needed
a second stent due to significant compression of the first
Table 4. Clinical Presentation and Management of Coronary Obstruction
(N  24)
Obstructed coronary artery
Left main 20 (83.3%)
Right 3 (12.5%)
Both coronary arteries 1 (4.2%)
Clinical presentation
Severe maintained hypotension 21 (87.5%)
ST-segment changes 13 (54.2%)
ST-segment elevation 6 (25.0%)
Ventricular arrhythmias 6 (25.0%)
Treatment
PCI attempted 23 (95.8%)
Successful 21 (91.3%)
Stent successfully implanted 19 (82.6%)
Guide-wire protection only 1 (4.4%)
Catheter manipulation removed the calcium 1 (4.4%)
Unsuccessful 2 (8.7%)
Wire crossing failure 1 (4.4%)
Stent implanted but no ﬂow 1 (4.4%)
Postmortem diagnosis 1 (4.4%)
Type of stent
BMS only 13 (65.0%)
DES only 6 (30.0%)
Both 1 (5.0%)
Complications
Need for cardiopulmonary resuscitation 9 (37.5%)
Need for hemodynamic support 6 (25.0%)
Compression requiring 2nd stent 3 (13.4%)
Conversion to open heart surgery 2 (8.3%)
Restenosis 1 (4.2%)
In-hospital death 2 (8.3%)
Hospital stay length, days 7 4
Values are n (%) or mean SD.
PCI percutaneous coronary intervention.implanted stent unresponsive to balloon post-dilation.Hence, one might argue for the use of stents with higher
radial force and routinely perform high-pressure post-
dilation with a noncompliant balloon. The reasons for these
findings are not yet understood; nonetheless, the struts from
the valve frame and most likely external compression from
the calcific native valve cusp might play an important role
(24,25). Importantly, up to 25% and 8% of the patients
required either mechanical hemodynamic support (cardio-
pulmonary bypass, intra-aortic balloon, tandem heart sup-
port) or conversion to open heart surgery, respectively,
highlighting the importance of performing these procedures
in highly experienced centers with cardiac surgery facilities.
Study limitations. The present study has the limitations
inherent to a systematic review that collects only the
information described in the publications. Therefore, there
might be relevant information omitted in the publications
that could shed some more light on this complication.
Indeed, imaging data (especially on CT) was not available in
all reported cases, and this prevented an appropriate evalu-
ation of the characteristics of the patient determining a
higher risk for the occurrence of this complication. In
addition, all the papers found in the published data were
either case reports or very small series, precluding compar-
ison with the entire TAVI population at risk. Additionally,
the reported patients might have tended to pursue a better
outcome than those who were not published (“selection
bias”).
Conclusions
Coronary obstruction remains a rare but potentially life-
threatening complication of TAVI. Baseline characteristics
from reported cases suggest that this complication occurs
more frequently in women with no prior CABG and in
patients receiving a balloon-expandable valve. Future stud-
ies will have to confirm these data and elucidate whether the
potential lower rate of coronary obstruction observed after
self-expandable valve implantation is due to a transcatheter
valve class effect or to differences between valve types with
regard to pre-specified recommendations on coronary ostia
height and aortic root dimensions. Also, although the
10-mm “safety cut-off” for coronary ostia height might help
to prevent coronary obstruction during TAVI, approxi-
mately one-half of the patients who had this complication
exhibited a coronary ostia height 10 mm, suggesting both
that a higher “safety cut-off” might be required and that
factors other than coronary height (dimensions of sinuses of
Valsalva and/or severe valve calcification) might probably
play an important role in the occurrence of this complica-
tion. The results of this study also suggest that the occur-
rence of persistent severe hypotension, irrespective of the
presence or absence of ST-segment changes, immediately
after valve implantation requires ruling out this complica-
tion. Importantly, PCI was a feasible and effective treatment
in Table
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460in most cases, although the rates of additional hemodynamic
support, conversion to open heart surgery, or stent compres-
sion requiring the implantation of a second stent remained
important. Future prospective studies, including consecutive
series of TAVI patients with this complication, are needed
to further evaluate the predictive factors and the most
appropriate clinical management of this important compli-
cation of TAVI.
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